Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07139548
PHASE3

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Sponsor: Guangdong Raynovent Biotech Co., Ltd

View on ClinicalTrials.gov

Summary

The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.

Official title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2025-08-31

Completion Date

2026-12-31

Last Updated

2025-08-24

Healthy Volunteers

No

Conditions

Interventions

DRUG

RAY1225

Administered SC

DRUG

Semaglutide

Administered SC

Locations (1)

Peking University People's Hospital

Beijing, Heibei, China